Topadur Pharma

News

8.9.22

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR Pharma AG has been selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team, supporters, and partners believing in us along the way!

Please check out the link below.

‍

Download Document Dokument herunterladen https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022 https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022

4.4.23

Press Release

TOPADUR appoints Pascal Brenneisen as Chief Executive Officer

TOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.

10.11.20

Press Release

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.

19.5.22

Press Release

TOPADUR together with the USZ / UZH was awarded CHF 607'000 by Innosuisse

Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR appoints Pascal Brenneisen as Chief Executive Officer

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR together with the USZ / UZH was awarded CHF 607'000 by Innosuisse

Investors

About us

Pipeline

Contact